Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...
Caesarea, Israel (ots/PRNewswire) - Epitomee Medical Ltd. (TASE: EPIT) announces today that the company leadership intends to present Epitomee's Oral Delivery of Biologics Platform at the 14th Annual PODD Conference - Partnership Opportunities in Drug Delivery, taking place in Boston, MA, October 28-29, 2024. ...
EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar - STADA announces EMA acceptance of Marketing Authorization Applications for AVT03, a proposed denosumab biosimilar to Prolia® (Bone Health) and Xgeva® (Oncology) - STADA holds marketing rights for AVT03 in Europe, as well ...
London (ots/PRNewswire) - Norgine (the "Company"), a leading European specialty pharmaceutical company, has today announced the appointment of Janneke van der Kamp as its new Chief Executive Officer (CEO), effective from 1 January 2025. Current CEO, Chris Bath, has stepped down from his role effective immediately. This change in leadership will support and enhance the Company's mission of bringing transformative medicines ...
Caesarea, Israel (ots/PRNewswire) - Epitomee's Ingestible Capsule, Offers a Safe and Effective Prescription Solution for Adults with BMI of 25-40 looking for Alternative Drug Free Solutions for Their Weight Management Needs alongside diet and exercise. Epitomee Medical Ltd. (TASE: EPIT), announced that the United States Food and Drug Administration (FDA) has officially ...
Ejby, Denmark (ots/PRNewswire) - Today Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Research Organization ("CRO"). Gentronix, now integrated into Scantox Group, is well recognized for its high-quality genetic toxicology services and strong scientific engagement, with ...
INSIGHTEC; Charles River Laboratories International, Inc.
Wilmington, Mass., Miami and Haifa, Israel (ots/PRNewswire) - Collaboration stands to advance novel therapeutic applications across multiple neurologic conditions Charles River Laboratories International, Inc. (NYSE: CRL) and Insightec, a global healthcare company dedicated to using focused ultrasound to transform ...
Bosch Healthcare Solutions GmbH
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, will be presenting the ACOU085 Phase 2 PROHEAR clinical study at the HansonWade 4th Inner Ear Disorders Therapeutics Summit in Boston (MA) from August ...
Berlin (ots) - French pharmaceutical giant Sanofi has confirmed it will invest 1.3 billion euros to expand insulin production in the western German city of Frankfurt am Main. Sanofi says the expansion will encompass around 36,000 square meters – the equivalent of five football fields – on the company’s existing BioCampus site. It will go operational in 2029. The project is being supported by the German national ...
Aachen, Germany (ots) - - Grünenthal acquires the pharmaceutical company Valinor Pharma, further strengthening Grünenthal’s footprint in the United States. - With the acquisition, Grünenthal becomes the global owner of Movantik® / Moventig® (naloxegol). - Since 2017, Grünenthal has invested more than €2 billion in successful M&A transactions, significantly ...
LAUDA DR. R. WOBSER GMBH & CO. KG
Alvotech and STADA add to strategic alliance through denosumab partnership - STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle ...
STADA welcomes CHMP positive opinion on extending indication for Kinpeygo - The CHMP adopted a positive opinion recommending a change to the terms of the marketing authorization of Kinpeygo for the treatment of adults with primary immunoglobulin A, now covering patients with a UPCR of ≥0.8 g/g - ...
London (ots/PRNewswire) - - Once-daily topical treatment of mild / moderate alopecia areata (AA) with 1% STS-01 met the primary efficacy endpoint of >30% Severity of Alopecia Tool (SALT) score improvement compared to patients receiving placebo ...
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK - Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® ...
Technische Universität München
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE What mucins can do in medicine Multi-purpose mucus They are in our eyes, on our tongues, and in our stomachs: Protective layers of mucus, a slime consisting primarily of mucins. These are molecules which bind water to form a natural lubricant. Researchers at the Technical University of Munich (TUM) use them to develop coatings for contact lenses and intubation tubes, healing ...
STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey - Total carbon emissions by STADA reduced by 25% between 2020 and 2023 - Around 45% of STADA’s electricity consumption now comes from renewable ...
Medison Pharma; Alnylam Pharmaceuticals
Zug, Switzerland (ots/PRNewswire) - - The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global alliance - Medison, the creator and leader of the multi-regional partnership category, will utilize its unique, unified platform for efficient ...
Brussels and Prague (ots/PRNewswire) - Zentiva, a Pan-European pharmaceutical company, joined the inaugural launch of the EU's Critical Medicines Alliance, held on April 24-25 in Brussels. This significant event, organized by DG HERA and the Belgian Presidency, convened leaders from across the healthcare industry to address the challenges of medicine supply resilience ...
Amsterdam (ots/PRNewswire) - Norgine B.V. today announced its first marketing authorisation application submissions on 10 April 2024, seeking approval for eflornithine in high-risk neuroblastoma (HRNB), via Project Orbis in Australia, Switzerland and the United Kingdom. This milestone supports Norgine's efforts to ...
